During the past seven years of this SPORE project, we were first to identify in pancreatic cancer the nearly ubiquitous inactivation of the pl6 gene, and the genetic inactivation of BRCA2, TGF-beta receptors I and II, activin receptor IB, LKB1/STK11 (Peutz-Jeghers), DPC4/SMAD4, mitochondrial genome, DCC, and mismatch repair genes including MLH1. We confirmed the mutations of MKK4 and identified a distinctive nature of K-ras wildtype tumors. The discoveries provided insights into tumor biology, familial aggregation, and histologic tumor classification now applied in clinical practice. Our long-term goal is to identify the metabolic and regulatory pathways that are altered reproducibly in pancreatic tumorigenesis in order to construct a general theory that explains tumor behavior, provides improved epidemiologic and diagnostic tools, and enables rational therapy. In the proposed grant period, we will acquire essential knowledge to advance this goal: 1) Identify novel genetic alterations in pancreatic cancer. We will apply techniques that have proven efficient in this effort, including the evaluation of sites of homozygous deletion and the consideration of candidate genes based on pathway relationships. 2) Extend the genetic discoveries made in pancreatic and other tumor systems. We will map the homozygome of pancreatic cancer; the genes contained within homozygous deletions are likely to include not only the mundane """"""""passenger genes"""""""", but also additional suppressor genes and biochemical defects that could suggest attractive therapeutic targets. Genes known to be altered in other tumor types will be examined in pancreatic cancer as an essential component in construction of a genetic basis for the disease. 3) Determine the clinical relevance of the genetic alterations identified. This has proven to be a highly successful application of this project. We will evaluate associations among known genetic alterations and a set of demographic, clinical, and histologic characteristics. This will be invaluable as a basis for clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-09
Application #
6630877
Study Section
Project Start
2002-07-01
Project End
2007-06-30
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118

Showing the most recent 10 out of 883 publications